DOI: 10.15415/jptrm.2015.31003

Clinical Symptoms and Therapies for Multiple Sclerosis

ASHWANI ARYA*[1], SAHIL KUMAR[2] AND RAKESH K SINDHU[3]

[1]Department of Pharmaceutical Education and Research, BPS Women University, South Campus, Bhianswal Kalan, Sonepat, Haryana, India

[2] School of Pharmacy and Emerging Science, Baddi University of Emerging Science Technology, Baddi, Solan, H.P, India

[3]Chitkara College of Pharmacy, Chitkara University, Rajpura, Patiala, Punjab, India

***Email ashwaniarya5@rediffmail.com**

Received: January 2, 2015| Revised: February 6, 2015| Accepted: April 2, 2015

Published online: May 29, 2015

Abstract Multiple Sclerosis (MS) is a chronic form, progressive and immune mediated central nervous system disorder that affects both adults and children. MS is characterized by the development of multiple lesions with the nerve fibers in the spinal cord, optic nerves and brain. Multiple sclerosis affects the approximately 2.5 million people worldwide. A triad of symptoms characterize the disease: fatigue, changes in sensation, ataxia, muscle weakness, dysarthria, dysphagia, visual problems, chronic or acute pain, difficulties of bladder and bowel. The diagnosis of Multiple Sclerosis is made on the foundation of the signs and symptoms, with magnetic resonance imaging and additional laboratory tests playing a helpful role. Every tests are non precise and simply supply supportive indication for diagnosis. A few people have a inadequate number of "relapses" or "attacks" and remain fairly healthy for decades, others may worsen rapidly from the time of analysis, through shortened lifespan and poor excellence of the life. The prognosis is problematical to forecast; it depends on the initial symptom, subtype of the illness, the individual patient's disorder characteristics. The substantial variability in multiple sclerosis manifestations leads to elevated figure of misdiagnoses each year, but advances in knowledge and pharmaceuticals are leading to more exact identification and successful management. Early diagnosis and management is essential in reducing the severity of disease.

Keywords: Multiple sclerosis, plaques, myelin, autoimmune disease.

Journal of Pharmaceutical Technology, Research and Management
Volume 3, No. 1,
May 2015
pp. 29–47

1. INTRODUCTION

Multiple Sclerosis (MS) is a chronic form, progressive and immune mediated central nervous system disorder that affects both adults and children (Amanda et al., 2014; Granziera & Sprenger, 2015). Typically, the route of the disease starts with random exacerbations and then slowly becomes progressive (Campstom and Coles, 2008 ; Amanda et al., 2014). During the course of the muktiple sclerosis, CNS is affected by axonal damage, gliosis, demyelination, remyelination & inflammation (Jezabel, 2015). Multiple sclerosis is characterized by the development of multiple lesions with fibers of nerve in the brain, and optic nerves (Campstom and Coles, 2008). Approximately 2.5 million peoples are affected worldwide from the multiple sclerosis (WHO, 2006). Multiple sclerosis usually more common in females than males (WHO, 2006 ; Rosati, 2001). The precise triggers of autoreactive T cell development remain to be totally understood, however, it is understandable that the myelin antigens are the key target. T cell activation results in cytokine release and recruitment of other immune cells that results in tissue damage not only to the myelin sheath but, more time and among repetitive attacks, to the underlying axons as well (Pivneva, 2009 ; Amanda et al., 2014). Demyelination and axonal damage impairs or interrupts nerve transmission, giving increase to signs and symptoms of the multiple sclerosis (WHO, 2006).

Multiple sclerosis is the most important human inflammatory demyelinating disease characterized by recurrent neurological relapses and/or progression that occur from multifocal white matter and cortical lesions within the central nervous system (Amanda et al., 2014). In individuals with multiple sclerosis, the immune trigger is unidentified, but the targets are myelinated central nervous system tracts (Compstom and Coles, 2008). The sheath of myelin influences the nerve impulse conduction. In multiple sclerosis the sheaths worsen to scleroses, which are tough plaques or scars in multiple regions (Calabrese et al., 2010). The disease is characterized by early stages relapsing remitting course (Costello, 1996). In the early stages there may be little harm to axons. Over moment the disorder enters an irreversible progressive phase of neurological deficit (Amanda et al., 2014). Acute relapses are caused by inflammatory demyelination, while disease progression is idea to outcome from axonal loss (Foxm et al., 2006). Each relapse causes further loss of nervous tissue and progressive dysfunction. In a few cases there may be the chronic progression lacking remission or acute illness rapidly foremost to death (Miller and Leary, 2007). Treatments effort to return function after an attack, avoid new attacks, and avoid disability. The prognosis is complicated to forecast; it depends on the initial symptom, subtype of the illness, the individual patient's disorder characteristics. The substantial variability in multiple sclerosis manifestations



Figure 1: The signs and symptoms of the multiple sclerosis (Campstom and Coles, 2008).

leads to a elevated figure of misdiagnoses each year, but advances in knowledge and pharmaceuticals are leading to more exact identification and successful management. Early finding and management is essential in reducing the severity of disease (Foxm et al., 2006; Miller and Leary, 2007).

2. CLINICAL SIGNS AND SYMPTOMS

A triad of clinically symptoms characterize the Multiple sclerosis are changes in the sensation (paraesthesia and hypoesthesia), ataxia, dysarthria, visual problems (like nystagmus, optic neuritis, or diplopia), muscle weakness,

Muscle spasms, dysphagia, fatigue, bladder and bowel and acute or chronic pain (WHO, 2006).

Multiple sclerosis be able to cause approximately any neurologic symptom since it be able to influence any area of optic nerve, brain and spinal cord. Disorder localized to the spinal cord may cause motor changes and sensory or relating one or both sides of the body or lower than a certain level of spinal cord (i.e., paraparesis or hemiparesis). Brainstem association may present as ataxia, diplopia, altered sensation. The inflammation of the optic nerve (optic neuritis) frequently presents as blurry vision among painful eye movements (WHO, 2006). Multiple sclerosis is usually seen as an developing myelopathy causing the asymmetric, ataxia, weakness of leg and spasticity. Extra frequent signs and symptoms of multiple sclerosis include memory changes, dysfunction of bowel and bladder, fatigue and affective disorders like depression (WHO, 2006). Similarly at arrival, deficits of cerebellar, autonomic functions, brain stem, sensory and motor are the most general clinical manifestations in further higher step of multiple sclerosis (Foxm et al., 2006).

3. DIAGNOSIS OF MULTIPLE SCLEROSIS

The diagnosis of multiple sclerosis is completed on the basis of the signs and symptoms, with laboratory tests and magnetic resonance imaging playing a helpful part in the diagnosis of multiple sclerosis. Every tests are non specific and simply supply supportive facts for diagnosis of multiple sclerosis (Foxm et al., 2006). In the majority instances, multiple sclerosis begins as a relapsing-remitting disease that, in several patients, becomes secondary progressive (Miller and Leary, 2007). The early stages of disease are related among relapses and gadolinium development on magnetic resonance imaging, which decrease among time still without the treatment (Poser and Brinar, 2004).

Multiple sclerosis is a medical identification, dependent on a cautious neurologic examination, complete history, and accommodating paraclinical investigations, counting magnetic resonance imaging scans, evoked potentials, CSF and blood tests to exclude confusing diagnoses. The classic multiple sclerosis investigative criteria are the proof of lesions in the central nervous system disseminated in time and space. In patients with clinically specific multiple sclerosis, brain magnetic resonance imaging reveals multifocal cerebral white matter lesions in extra than 95% of patients and in 75%–85% there are focal spinal cord lesions (Foxm et al., 2006).

Magnetic resonance imaging is the only mainly functional laboratory test in the diagnosis of multiple sclerosis (Filppi et al., 2011; Poser and Brinar, 2004;). Visual evoked potentials are mainly frequently employed in medical follow. Since multiple sclerosis affects anterior optic pathway (Tsang & Macdonell,

2011). The brainstem auditory evoked potentials have also been used in the identification of disease (Tsang & Macdonell, 2011). The cerebrospinal fluid examination has been used to maintain the diagnosis of multiple sclerosis for a extended time. The occurrence of myelin basic protein in the cerebrospinal fluid in patients of multiple sclerosis may be extremely suggestive of action of multiple sclerosis development but its nonexistence does not rule out active disease (Filppi et al., 2011; Poser and Brinar, 2004). There is no particular diagnostic test for disease. The diagnosis is based on proof of at least two different lesions (plaques or scars) in the white matter of the central nervous system (the space dissemination criterion); at least two different episodes in the disease route (the time dissemination criterion); and chronic inflammation of the central nervous system, as determined by investigation of the cerebrospinal fluid in the inflammatory criterion (Marvin, 2012; Filppi et al., 2011).

4. CLASSIFICATION OF MULTIPLE SCLEROSIS

Multiple sclerosis is basically divided as follows:

4.1 Relapsing-remitting multiple sclerosis:

Episodes of acute deterioration of neurological function, among a few amount of advance (the mostly frequent form) and no progression in between. About 80% of patients will primarily present this form of disease, in which there is unpredictable attack (relapses) through which latest symptoms come into view or existing symptoms become more severe. The relapses can last for unstable episode (day or month) and there is partial or entire improvement / remission (Compstom and Coles, 2008).

4.2 Primary-progressive multiple sclerosis

Continuing worsening of disease without distinct relapses, which affects approximately 10-15% of every multiple sclerosis patients, is characterized by a be deficient in of distinct attacks, but among slow onset and then steadily worsening symptoms (Miller and Leary, 2007).

4.3 Secondary-progressive MS

Relapsing-remitting primarily, eventually converting to a progressive form among a gradual loss of function (WHO, 2006). About 50 % of patients among relapsing/remitting multiple sclerosis will enlarge secondary progressive multiple sclerosis within 10 years, and 80 % will have developed this multiple sclerosis within 20 years of disease onset (Rovaris et al., 2006).

4.4 Progressive-relapsing MS

Progressive disease from beginning, among continuing disease progression and acute relapses (WHO, 2006; Compstom and Coles, 2008).

5. PATHOPHYSIOLOGY OF MULTIPLE SCLEROSIS

MS is a nondescript term that refers to "multiple scars" that collect in the spinal cord and brain (Ascherio and Munger, 2007). The clinical heterogeneity of the disease is reflected in the diverse types and stages of the disorder. The demyelinative diseases of the CNS are characterized by loss of myelin among variable axons loss. Multiple sclerosis is the main demyelinative disease of the CNS (Amanda et al., 2014 ; Chard et al., 2002).

Multiple sclerosis is a biphasic disease, whereby lesions occur in specific areas of the brain and spinal cord, causing interference in the blood-brain barrier (Minagar and Alexander, 2003). This leads to the infiltration of leukocytes, causing inflammation. When lesions happen in the brain, axons will ultimately go through demyelination by immune cells, and the effectiveness of action potential transmission will be affected. Remyelination can arise in the premature stages of the disease, although the recurring lesions avoid the sufficient repair (Lucchinetti et al., 2000). This leads to the deterioration of neurons and axons, consequential in a variety of levels of damage to the nervous system, including sensory impairment and motor impairment (Foxm et al., 2006; Lucchinetti et al., 2000). Through the early period of the inflammatory period, lymphocytes with encephalitogenic potential are activated in the periphery by factors like infection or extra metabolic stress. These activated T cells seek access into the central nervous system via connection to a receptor on endothelial cells. This contact, mediated by production of matrix metalloproteinases, which allows a breach in the blood-brain barrier, leading to further upregulation of the molecules of endothelial adhesion and supplementary influx of inflammatory cells (Chari, 2007; Minagar and Alexander, 2003). The T cells create inflammatory cytokines that magnetize macrophages that contribute to demyelination. The degenerative factor of disease is supposed to reflect axonal degeneration and loss (Lucchinetti et al., 2000; Amanda et al., 2014; Chari, 2007). There is also proposition that inflammatory cells complement and antibodies can give to injury of the axonal (Lucchinetti, 2008; Ascherio and Munger, 2007).

Multiple sclerosis is related with a variety of demyelination that depends on clinical categorization and duration of the disease. The multiple sclerosis is characterized by plaques composed of demyelination, neuronal, strocytic scars and axonal degeneration (Ascherio and Munger, 2007; Lucchinetti et al., 2000). At the core of the inflammatory development are leukocytes that

have entered the central nervous system CNS (Karussis, 2014; Lassmann et al., 2007). Lymphocytes planned to identify myelin antigens are consideration to trigger a cascade of procedures resulting in the development of an demyelinating lesion and acute inflammatory (Karussis, 2014). These lesions characteristically extend in white matter in the course of targeting of the myelinating cell (the oligodendrocyte) and myelin sheath (Lucchinetti et al., 2000). The persistent inflammation attributable to the leukocytes, as well as a myriad of extra inflammatory mediators, leads to the damage of myelin and the gradual progression of neurocognitive decline. The progression of disease is the consequence of a mixture of factors, including the accumulative axons loss due to a continued difficult of responses of the inflammation (Franklin and French, 2008).

Multiple sclerosis is a T-cell autoimmune disease. It is characterized by a relapsing-remitting followed through a progressive phase. Relapses are motivated via the adaptive immune system and involve waves of T helper cell 1, T helper cell 17 and cells of CD8 that permeate the nervous system and aggravate attack. These cells are modulated by regulatory T-cells and B-cells (Lucchinetti et al., 2000). The penetration of T cells into the nervous system initiates a multifaceted immunological cascade consisting of epitope spreading, which triggers attacks, and creation of the innate immune system, which leads to the chronic inflammation. The secondary progressive stage is due to neurodegeneration triggered by the inflammation and is motivated by the innate immune system (Amanda et al., 2014).

5.1 Immune Dysfunction and Damage to CNS:

MS is characterized by means of the development of multiple lesions with the nerve fibers in the spinal cord and brain. The key points as follows:

1. Axons, the nerve fibers that transmit the information via the electrical signals.
2. Myelin, the fatty substance that wraps in the region of the axons.
3. Oligodendrocytes, the cells that create the myelin.
4. Blood vessels that supply nutrients and oxygen.
5. Inflammatory factors, such as cytokines
6. T-cells, a form of white blood cell
7. Antigen-presenting cells, which initiate the myelin antigen to the T cell.

Through this immune response, cells that recognize the antigens are somehow triggered to understand one of the mechanism of myelin as foreign (Amanda et al., 2014). When antigen presenting cells initiate the myelin antigen to the T cells, the T cells go by the blood–brain barrier and accumulate

an attack on the myelin (Chard et al., 2002). The additional inflammatory factors, like cytokines, are released, and the end result is an immunologic flow that produces tissue harm to myelin sheath and axons (Schrjver et al., 1999). This "demyelination" makes the broadcast of information by axons more complicated finally; there is intervention among the transmission of nerve impulses from sensory organs to the central nervous system and from the central nervous system to the muscles. The axonal damage can be division of this critical course still early in the disorder and may outcome in permanent neuronal transmission loss (Chard et al., 2002; Pascual et al., 2007). The Inflammatory episodes happen in the appearance of periodic acute attacks, the inflammation subsides, impaired role is frequently improved either completely or incompletely (Lucchinetti et al., 2000). The process of "remyelination" or reversal of inflammation can happen the permanent harm may take place at any time (Chari, 2007). The myelin loss and axonal are major pathological features of disase and be able to be straight caused by immune cells. Intermediates can generate the cascae of immune that further develop inflammatory-mediated central nervous system damage (Trapp et al., 2007; Basso et al., 2008).

5.2 Possible Triggers

Multiple sclerosis is certainly an autoimmune disorder and the factors that trigger an attack on the brain cord and brain's white matter remain unknown (Weiner, 2004). A figure of hypotheses are being explored, one being the role of viruses in the disease (Sotelo et al., 2008). Peripheral blood antibody titers to various viruses are prominent in disease. These comprise Epstein–Barr, varicella zoster, rubella, human herpes virus 6 and vaccinia. In a few cases, virus-specific antibody is too detected in the cerebrospinal fluid, and a few viruses, mainly human herpes virus -6, have been detected close to the characteristic brain lesions of a few personnel among the disease (Sotelo et al., 2008; Friedman, 1999). The significance of these results to the pathophysiology of the multiple sclerosis remains to be determined. Its causes that supply to its heterogeneity are chiefly unidentified, even though it is probable a multifaceted trait with environmental and genetic components (Foxm et al., 2006; Rosati, 2001). Epidemiological conclusion support equally the genetic and environmental hypotheses, and these forces likely interrelate to construct entity disorder susceptibility and influence the course of the disase (Ascherio and Mungar, 2007; Dyment et al., 2004).

The risk of disease in family of patients is 7 times superior than in the general people. The monozygotic twins are 25.9% and dizygotic twins are only 2.3% concordant. The patients multiple sclerosis communicate with elevated occurrence certain class I and II HLA antigens, chiefly DW2 and

DR (Dyment et al., 2004; Weinshenkar et al., 1998 ; Hafler et al., 2007 ; Caillier et al., 2008). The genes that contribute to MS susceptibility have not been identified. The HLA DR2 allele has been associated with MS in many populations (Trapp et al., 2007). It seems unlikely that any other single genes contribute a significant risk. Genetic factors may also determine disease course and severity, but HLA polymorphisms are not significant contributors. Polymorphisms in the interleukin-1b-receptor and interleukin- 1b-receptor antagonist genes, the apolipoprotein E gene, and immunoglobulin Fc receptor genes have been associated with disease course (Schrijver et al., 1999; Myrh et al., 1999 ; Evangelou et al., 1999). Multiple sclerosis is consideration to be an autoimmune disease which is probably triggered through a infection of virus. The environmental and genetic susceptibility participate essential roles in its pathogenesis of multiple sclerosis (Myrh et al., 1999; Hafler et al., 2007).

The inflammation of the central nervous system is the main cause of nervous system harm in multiple sclerosis. The accurate factors that start inflammation are unidentified, but it is usually thought that multiple sclerosis is caused by environmental in a genetically susceptible host that activate a response of T-cell autoimmune against the central nervous system. The current findings have begun to recognize genes that are linked with multiple sclerosis, and they are associated to immune system (Dyment et al., 2004). The histocompatibility complex is the major genetic aspect in multiple sclerosis, which overshadows further susceptibility genes that have been recognized (example, interleukin-2, interleukin-7). The major histocompatibility composite is mainly associated to multiple sclerosis through affecting together the immunoregulatory and immune repertoire is connected to severity of the disease (Hafler et al., 2007). Even though viruses can activate multiple sclerosis relapses, there is no perfect facts that there is an multiple sclerosis virus or an continuing chronic infection of the nervous system (Weiner, 2004; Sotelo et al., 2008). The course of disease is extremely diverse and unpredictable. In a large amount of patients, the disease is characterized primarily via episodes of reversible deficits of neurological, which is frequently followed by progressive neurological worsening (Rovaris et al., 2006; Weiner, 2004). As chronic troubles accumulate, the multiple sclerosis may become further steadily progressive, among no acute relapses and fewer. The course of multiple sclerosis is irregular and variable on a everyday and an basis of entity patient (Bagert et al. 2002).

6. THERAPEUTIC MANAGEMENT

The efficient managing of multiple sclerosis is difficult and draws on various disciplines, such as physiotherapists, neurologists, speech therapists, counselors, occupational, social workers as well as consultants, nurses, pharmacists and

general practitioners. There has been no exact management for the disease. The therapies used to take care of multiple sclerosis are targeted at diverse aspects of the disorder and be able to be categorized into disease modifying therapies, treatments used in acute exacerbations and medicines used to treat complications of the disease (Cree, 2013 ; Rovaris et al., 2006).

6.1 Disease modifying therapies:

The mainly possible assumption relating to the reason of multiple sclerosis is that it is an unusual and autoimmune response. Hence, mainly drugs in this class place out to change the immune system, either by suppression or stimulation or (Nakahara et al., 2012).

6.1.1 Interferon's

Three forms of beta interferon (Rebif, Avonex and Betaserond) have currently been accepted by the Food and Drug Administration for management of relapsing-remitting multiple sclerosis. Beta interferon has been exposed to the progression of physical disability and may diminish the number of exacerbations. When attacks do take place, they tend to be shorter and less rigorous (NINDS, 2015).The interferon's are naturally taking place cytokines and amino acids. Gamma interferon formed by T cells is consideration to stimulate macrophages which then destroy the myelin directly and has been exposed to exacerbate multiple sclerosis. Interferon's alpha and beta are formed by several different cells, counting fibroblasts, endothelial cells and macrophages. Interferon beta is recognized to have immunomodulatory effects (Rudick et al., 2014). Of the beta interferon's, (IFNB-1b and IFNB-1a) have been exposed to be mainly favorable in multiple sclerosis. IFNB-1a and IFNB -1b are related in their in vivo pharmacokinetics and biological action and (Cree, 2013).

6.1.2 Glatiramer acetate (copolymer-1)

The Food and Drug Administration furthermore has accepted a copolymer I (Copaxone), synthetic type of myelin basic protein for the management of relapsing-remitting multiple sclerosis. Copolymer I has a small number of side effects, and findings specify that the representative can decrease the relapse rate (NINDS, 2015). It was unintentionally exposed through attempts to provoke experimental allergic encephalomyelitis in animals. Its mode of action has not been distinct, even though it is consideration to involve inhibition of suppression of T-cell activation and lymphocyte migration (Miller et al., 1998). It is given every day at a dose of 20 mg sc and is well tolerated with the the

majority of the frequent adverse experience being injection site reaction. A two year study established a 29% decrease in relapse rate (Johnson et al., 1995).

6.1.3 Intravenous immunoglobulin (IgG)

In a two-year randomized controlled trial, around 150 patients with RRMS showed a favourable outcome on relapse rate in the management, who acknowledged intravenous immunoglobulin (Comabella & Khoursy, 2012).

6.1.4 Cytotoxic immunosuppressants:

Immunosuppressant drugs such as cyclophosphamide, mofetil, mitozantrone, azathioprine and cyclosporin offer only modest benefits and in general, these benefits are outweighed by their side Effects (Smith et al., 2005; Millefiorini et al, 1997; Yudkin et al., 1991; Goodkin et al., 1995).

6.1.5 Low-dose methotrexate

Once weekly treatment of methotrexate at a low dose (7.5 mg) has been shown to slow significantly the progression of chronic progressive MS (Goodin et al., 2002).

6.1.6 Cladribine:

Cladribine (2-chlorodeoxyadenosine) is a purine antimetabolite and its use in MS is controversial. Side effects included thrombocytopenia, bone marrow suppression and herpes zoster attacks (Sipe et al., 1994; Romine et a., 1999).

6.1.7 Linomide-

Linomide (quinoline-3-carboxamide) is a synthetic immunomodulator that acts by stimulating killer T cells. It also interferes with antigen presentation (Polman & Hartung, 1995). Linomide (2-5 mg daily by mouth) has been shown to suppress disease activity in those with SPMS (Karussi et al., 1996). However, phase III trials were prematurely stopped due to a higher than expected incidence of myocardial infarction in the linomide-treated group (Tremlett and Luscombe, 1998)

6.1.8 Anti- α 4 integrin (Antegren)

Antegren is a monoclonal antibody directed alongside 4 integrin, a cell adhesion molecule implicated in immune cell migration (Johnson, 2007; Tubridy et al., 1999).

6.2 Treatments used in acute exacerbations

Acute exacerbation in the neurological condition of a patient with multiple sclerosis can be due to an event of electrolyte imbalance, inflammatory demyelination, intercurrent infection, drug intoxication and fever. In a relapse, neurological worsening usually occurs over a number of days and improvement takes weeks to months. Corticosteroids are useful in accelerating recovery from an acute exacerbation, but do not affect long - term disability. Corticosteroids are currently typically used in treating relapses and are idea to perform by reducing inflammation, oedema and accordingly resolving obstruct the conduction. They assist to the rate of improvement but do not influence the ultimate extent of improvement. No ending has been reached as to which steroid is absolutely superior. The mainly well-liked option is iv methyl prednisolone (Bugert et al., 2012). The beneficial action of corticosteroids in disease is probably two-fold, involving both their immunosuppressive and anti-inflammatory effects. In MS, corticosteroids reduce inflammation and oedema around the plaques, which lowers the pressure on the axons and allows better nerve impulse conduction. Corticosteroids also repair the damaged BBB by reducing inflammation and hence reducing the passage of white blood cells and other inflammatory mediators through to the CNS. Immunosuppressant action of corticosteroids might exacerbate, the infectivity, which in a few cases, may guide to septicaemia. The side effects comprise of anxiety, insomnia and restlessness. Psychosis, depression, or euphoria can also happen (Barnes et al., 1997). Prednisolone in oral form may be efficient in decrease acute attacks (La Mantia et al., 1994). The remedial plasma exchange has been exposed to advantage the patients among severe relapses so as to not responded to the intravenous corticosteroids (Amanda et al., 2014).

6.3 Neurorehabilitation

The Philosophy of neurorehabilitation, which emphasizes patient education and seff –management, is well suited to meet the complex and variable needs of MS (Thompson, 2005). Neurologists will be the major physicians concerned, but depending on the indication, doctors of further medical specialties may also be helpful. Allied treatments such as physiotherapy, speech and language therapy or occupational therapy can also help to manage some symptoms and maintain the quality of life (Ghaffar & Feinstein A, 2007; Benedict & Bobholz, 2007 ; Steultjens, 2005). Due to the small number study of randomized controlled, there is inadequate confirmation of the largely usefulness of individual remedies disciplines, though there is fine facts that definite approaches like psychology therapies, exercise, energy conservation

instruction, and mainly cognitive behavioural approaches and are useful (Ghaffar & Feinstein, 2007).

6.4 Complementary and alternative therapies

Many community among the multiple sclerosis apply a few variety of alternative or complementary remedy. These therapies approach from various cultures, disciplines, traditions and encompass techniques as unusual as aromatherapy, ayurvedic medicine, acupuncture, energy therapies, touch, physical movement disciplines like yoga, herbal supplements. Because of the threat of connections between alternative and additional conventional therapies, community among multiple sclerosis should talk about all the therapies they are using among their doctor. Even though the herbal supplements are well thought-out "natural," they have biologically-active ingredients that could have unsafe effects on their individual or interrelate harmfully among further medications (NINDS, 2015).

6.5 What research is being done?

The latest discoveries are persistently changing the managing option. A few researchers are investigating area that shows potential avenues for therapeutics, such as medicines that would care for myelin cells from harm or that could facilitate them improve after an attack. Interfering among the substances and inflammatory cells implicated in the progress of multiple sclerosis lesions or prevent the immune-system cells from passage the blood-brain barrier could potentially prevent an attack (NINDS, 2015). Food and Drug Adminstartion approved drugs to use for relapsing forms of MS in adults include teriflunomide and dimethyl fumarate. An immunosuppressant treatment, Novantrone (mitoxantrone), is accepted by the FDA for the management of highly developed or chronic multiple sclerosis. The FDA has also accepted (Ampyra) dalfampridine to improve walking in persons with multiple sclerosis. One natalizumab (Tysabri), monoclonal antibody, was exposed in clinical trials to extensively decrease the incidence of attacks in community with relapsing multiple sclerosis and was permitted for marketing through the U.S. Food and Drug Administration in 2004. However, in 2005 the drug's producer voluntarily suspended marketing of the medicine later than numerous information of significant adverse effects (NINDS, 2015). In 2006, the Food and Drug Administration once more permitted sale of the drug for disease but under strict treatment strategy relating infusion centers. While steroids do not influence the track of multiple sclerosis over time, they can decrease the severity and duration of attacks in a few patients. Spasticity, which can happen either as a sustained stiffness caused by enlarged muscle tone or as spasms,

is generally treated with muscle relaxants and tranquilizers like baclofen, dantrolene, diazepam, tizanidine and clonazepam. Exercise and physical rehabilitation can facilitate conserve remaining utility. Even though progress of optic symptoms frequently occurs even lacking management, a small course of management with intravenous (Solu-Medrol) methylprednisolone followed by cure with oral steroids is occasionally used (NINDS, 2015).

There are a lot of novel treatment that have been exposed to avoid the development of new multiple sclerosis lesions in small studies. These treatments are at the moment being experienced in a big number of patients of multiple sclerosis in Phase-III clinical trials. These comprise daclizumab, rituximab, ocrelizumab, alemtuzumab, ladribine, laquinimod, fumaric acid and teriflunamide (NINDH, 2015). Investigators are demanding to extend conduct to assist brain cells called oligodendrocytes create new myelin in regulate to repair damaged cells and strengthen of the spinal cord and brain (NINDS, 2015).

Researchers will recognize molecular biomarkers and brain imaging related with multiple sclerosis disease progression, susceptibility and treatment response profiles. Additional advances in understanding the environmental and genetic causes of disase will help categorize those at superior risk for the disorder. Investigate on interactions of neuroimmune and neurodegeneration processes and repair will guide to a novel generation of neuroprotective treatments that will complement recent multiple sclerosis treatments. These neuroprotective agents will facilitate to reduce, avoid or even restore the harm to nerve fibers that can cause long-standing improgressive impairments (NIH, 2010).

Multiple sclerosis is a multifaceted disorder with a number of mechanisms contributing simultaneously to its pathophysiology. Biomarkers, accompanying and able to dissect these processes promise tremendous value for diagnostics for disease stages, prediction of disease course, improved prognosis for treatment success, treatment selection and, and the assessment of new therapeutics. however it is suspect that one of these markers could role as a true substitute, biomarkers can supply insight into the mechanism of action of a medicine (NINDS, 2015). The overall course and degree of disability of disease varies. The investigation for novel drug management for disease is gaining momentum and the future looks brighter for the management of multiple sclerosis (NINDS, 2015).

CONCLUSION

Multiple sclerosis is a chronic, inflammatory and autoimmune disease of the central nervous system. Multiple sclerosis is among the mainly general causes of neurological disability in men and women. The focal areas of demyelination

and relative axonal protection on a conditions of inflammation and the gliosis signify the pathological features of the disease. The course of multiple sclerosis is unpredictable and variable on a day-to-day and an individual patient basis. The existing therapies for multiple sclerosis comprise anti-inflammatory agents, which facilitate to prevent the episodic relapses, but are less efficient at preventing long-standing disability. Scientists suppose that therapies that support myelin repair might improve disability of neurologic in community with multiple sclerosis. The development complete so far in the pathogenesis of the disorder will agree to a improved understanding of the mechanisms implicated in its development and so, further exact treatments be able to be developed to ensure a improved excellence of life of the affected patients of the multiple sclerosis.

REFERENCES

[1] Amanda, L.H., Kevin, C.O. & David, A.H. (2014). Multiple Sclerosis. The Autoimmune Diseases, (**5**), 735–756

[2] Arnon, R., Sela, M., Teitelbaum, B. (1995). New insights into the mechanism of action of copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo- controlled trial. Neurology, **45**, 1268-76. http://dx.doi.org/10.1212/WNL.45.7.1268

[3] Ascherio, A. & Munger, K.L. (2007). Environmental risk factors for multiple sclerosis. Part I: the role of infection". Ann. Neurol, **61 (4)**, 288–99. http://dx.doi.org/10.1002/ana.21117

[4] Bagert, B., Camplair, P. & Bourdette, D. (2002).Cognitive dysfunction in multiple sclerosis: natural history, pathophysiology and management. CNS Drugs, **16**:445–55 http://dx.doi.org/10.2165/00023210-200216070-00002

[5] Barnes, D., Hughes, R.A., Morris, R.W., Wade, J.O., Brown, P. & Britton T. (1997). Rondomised trial of oral and intravenous mehylprednisolone in acute relapses of multiple sclerosis. Lancet 1997, 349, 902-906. http://dx.doi.org/10.1016/S0140-6736(96)06453-7 http://dx.doi.org/10.1016/S0140-6736(05)62665-7

[6] Basso, AS., Frenkel, D., Quintana, FJ., et al. (2008). Reversal of axonal loss and disability in a mouse model of progressive multiple sclerosis. J Clin Invest, **118**, 1532–1543. http://dx.doi.org/10.1172/JCI33464

[7] Beck, R.W. (1995). The opticneuritis treatment trial: three-year follow- up results. Arch Opthalmol, **113**, 136-137. http://dx.doi.org/10.1001/archopht.1995.01100020014004

[8] Benedict, R.H. & Bobholz, J.H.(2007). Multiple sclerosis. Seminars in neurology, **27 (1)**, 78–85. http://dx.doi.org/10.1055/s-2006-956758

[9] British and Dutch, M.S.(1998). Azathioprine Trial Group. Doublemasked trial of azathioprine in multiple sclerosis. Lancet, **2**, 179-180.

[10] Caillier, SJ., Briggs, F., Cree, BA., et al. (2008). Uncoupling the roles of HLA-DRB1 and HLA-DRB5 genes in multiple sclerosis. J Immunol, 181, 5473–5480. http://dx.doi.org/10.4049/jimmunol.181.8.5473

[11] Calabrese, M., Filippi, M. & Gallo, P.(2010). Cortical lesions in multiple sclerosis. Nature Reviews Neurology, **6**,438-444 http://dx.doi.org/10.1038/nrneurol.2010.93

[12] Chard, D., Griffin, C., McLean, M., Kapeller, P., Kapoor, R., et al. (2002). Brain metabolite changes in cortical grey matter and normal-appearing white matter in clinically early relapsing-remitting multiple sclerosis. Brain,**125(10)**, 2342-2352. http://dx.doi.org/10.1093/brain/awf240

[13] Chari, D.M. (2007). Remyelination in multiple sclerosis. Int. Rev. Neurobiol, **79**, 589–620. http://dx.doi.org/10.1016/S0074-7742(07)79026-8

[14] Comabella, M. & Khoury, S. (2012). Immunopathogenesis of multiple sclerosis. Clinical Immunology,**142(1)**,2-8 http://dx.doi.org/10.1016/j.clim.2011.03.004 http://dx.doi.org/10.1016/j.clim.2011.11.008

[15] Compstom, A. & Coles, A. (2008). Multiple sclerosis. Lancet, **372:** 1502-17. http://dx.doi.org/10.1016/S0140-6736(08)61620-7

[16] Costello, E. (1996). Exercise prescription for individuals with multiple sclerosis. Neurology Report, **20**, 24-30. http://dx.doi.org/10.1097/01253086-199620020-00016

[17] Cree, B.A.C. (2013). Update on reproductive safety of current and emerging disease-modifying therapies for multiple sclerosis. Mult Scler, **19**, 835-843. http://dx.doi.org/10.1177/1352458512471880

[18] Dyment, D.A., Ebers, G.C. & Sadovnick, A.D. (2004). Genetics of multiple sclerosis". Lancet Neurol, 3 (92), 104–10. http://dx.doi.org/10.1016/S1474-4422(03)00663-X

[19] Evangelou, N., Jackson, M. & Beeson, P.J. (1999). Association of the APOE epsilon4 allele with disease activity in multiple sclerosis. J Neurol Neurosurg Psychiatry, **67**, 203– 205. http://dx.doi.org/10.1136/jnnp.67.2.203

[20] Fazekas, F, Deisenhammer, F., Strasser, F.S, Nahler, G. & Mamoli, B. (1997). Randomised placebo-controlled trial of monthly intravenous-immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet, **349:**589-93. http://dx.doi.org/10.1016/S0140-6736(96)09377-4

[21] Filippi, M., Rocca, M.A., De, Stefano. N., Enzinger, C., Fisher, E., Horsfield, M.A., Inglese, M., Pelletier, D., Comi, G. (2011). Magnetic resonance techniques in multiple sclerosis: the present and the future. Arch. Neurol, **68 (12)**,1514–1520. http://dx.doi.org/10.1001/archneurol.2011.914

[22] Foxm, R.J., Bethouxm F., Goldman, M.D., Cohen, J.A. (2006). Multiple sclerosis: advances in understanding, diagnosing, and treating the underlying disease. Cleve Clin J Med, 73(1), 91-102. http://dx.doi.org/10.3949/ccjm.73.1.91

[23] Franklin, R., French-Constant, C. (2008). Remyelination in the CNS: from Biology to Therapy. Nat Rev Neurosci, **9**, 839-855. http://dx.doi.org/10.1038/nrn2480

[24] Friedman, J.E., Lyons, M.J., Ablashl, D.V., Whitman, J.E., Edgar, M., Koskiniemi, M., Vaheri, A. & Zabriskie, JB. (1999). The association of the human herpesvirus-6 and MS. Mult Sclerosis, **5**, 355–362. http://dx.doi.org/10.1177/135245859900500509 http://dx.doi.org/10.1191/135245899678846311

[25] Ghaffar, O. & Feinstein, A. (2007). The neuropsychiatry of multiple sclerosis: a review of recent developments. Curr Opin Psychiatry, **20 (3)**: 278–285.

[26] Goodin, D.S., Frohman, E.M., Garmany, G.P., et al. (2002). Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology, 58,169-178. http://dx.doi.org/10.1212/WNL.58.2.169

[27] Granziera, C. & Sprenger, T. (2015). Brain Inflammation, Degeneration, and Plasticity in Multiple Sclerosis.Brain Mapping, 917–927.

[28] Hafler, D.A., Compston, A., Sawcer, S., et al. (2007). Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med, 357 : 851– 862. http://dx.doi.org/10.1056/NEJMoa073493

[29] Isaac, C., Genton, M., Jardine, C., Grochowski, E. & Palmer, M. (1988). Multiple sclerosis: a serial study using MRI in relapsing patients. Neurology, 38, :1511-5. http://dx.doi.org/10.1212/WNL.38.10.1511

[30] Jezabel, Varadé., Marta García, Montojo., Belén D.L.H., Iris, Camacho., Ángel, García-Martínez ., Rafael, Arroyo., Roberto, Álvarez-Lafuente. & Elena, Urcelay. (2015). Multiple sclerosis retrovirus-like envelope gene: Role of the chromosome 20 insertion. BBA Clinical, 3, 162–167. http://dx.doi.org/10.1016/j.bbacli.2015.02.002

[31] Johnson, K.P. (2007). Control of multiple sclerosis relapses with immunomodulating agents. J. Neurol. Sci, 256 (1): 23–28. http://dx.doi.org/10.1016/j.jns.2007.01.060

[32] Johnson, K.P., Brooks, B.R., Cohen, J.A., Ford, C.C., Goldstein, J. & Lisak RP. (1995). Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial. Neurology, 45:1268-1276. http://dx.doi.org/10.1212/WNL.45.7.1268

[33] Karussi, D., Meiner, Z., Lehmann, D., Gomori, J.M., Schwarz, A. & Linde, A. (1996). Treatment of secondary progressive multiple sclerosis with the immunomodulator linomide: a double - blind, placebo-controlled pilot study with monthly MRI evaluation. Neurology, 47:341-346. http://dx.doi.org/10.1212/WNL.47.2.341

[34] Karussis, D. (2014). The diagnosis of multiple sclerosis and the various related demyelinating syndromes: A critical review. Journal of Autoimmunity, **48**, 134-142. http://dx.doi.org/10.1016/j.jaut.2014.01.022

[35] La, M.L., Eoli, M., Milanese, C., Salmaggi, A., Dufour, A., Torri, V. (1994). Double - blind trial of dexamethasone versus methyl prednisolone in multiple sclerosis acute relapses. Eur Neurol, **34**:199-203. http://dx.doi.org/10.1159/000117038

[36] Lassmann, H, Bruck, W. & Lucchinetti, C.F. (2007). The immunopathology of multiple sclerosis: an overview. Brain Pathol, **17:** 210–218. http://dx.doi.org/10.1111/j.1750-3639.2007.00064.x

[37] Lucchinetti, C. (2008). Pathological heterogeneity of idiopathic central nervous system demyelinating disorders. Curr Top Microbiol Immunol, **318**, 19-43. http://dx.doi.org/10.1007/978-3-540-73677-6_2

[38] Lucchinetti, C., Brück, W., Parisi, J., Scheithauer, B., Rodriguez, M., Lassmann, H. (2000). Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann. Neurol. **47 (6)**, 707–717. http://dx.doi.org/10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q

[39] Maeda, A., Sobel, R.A. (1996). Matrix metalloproteinases in the normal human CNS, microglial nodules and multiple sclerosis lesions. J Neuropathol Exp Neuro, **55** : 300-309. http://dx.doi.org/10.1097/00005072-199603000-00005

[40] Marvin, M.G. (2012). Multiple Sclerosis Review. Pharmacy and Therapeutic. 37(3),175–184.

[41] Millefiorini, E., Gasperini, C., Pozzilli, C. D., Andrea, F., Bastianello, S. & Trojano, M. (1997). Randomised placebo – controlled trial of mitozantrone in relapsing - remitting multiple sclerosis. J Neurol, **244**:153-159. http://dx.doi.org/10.1007/s004150050066

[42] Miller, A., Shapiro, S., Gershtein, R., Kinarty, A., Rawashdeh, H. & Honigman S.(1998). Treatment of multiple sclerosis with copaxone: implicating mechanisms of Th1 to Th2/Th3 immune- deviation. J Neuroimmunol, **92**:113-21. http://dx.doi.org/10.1016/S0165-5728(98)00191-X

[43] Miller, D.H. & Leary, S.M. (2007). Primary-progressive multiple sclerosis. Lancet Neurol, **6 (10)**, 903–912. http://dx.doi.org/10.1016/S1474-4422(07)70243-0

[44] Minagar, A. & Alexander, J. (2003). Blood-brain barrier disruption in multiple sclerosis. Multiple Sclerosis, **9**, 540-549. http://dx.doi.org/10.1191/1352458503ms965oa

[45] Myrh, KM., Raknes, G., Nyland, H., Vedeler, C. (1999). Immunoglobulin G Fc-receptor (Fc g R) IIA and IIIB polymorphisms related to disability in MS. Neurology, **52**, 1771–1776. http://dx.doi.org/10.1212/WNL.52.9.1771

[46] Nakahara, J., Maeda, M., Aiso, S., Suzuki, N. (2012). Current concepts in multiple sclerosis: autoimmunity versus oligodendrogliopathy Clinical reviews in allergy & immunology, **42 (1)**, 26–34 http://dx.doi.org/10.1007/s12016-011-8287-6

[47] National Institute of Neurological Disorders and Stroke. (2015). Multiple sclerosis hope through research.

[48] National Institutes of Health. (2010). Fact sheets multiple sclerosis.1-2.

[49] Pascual, A.M., Martínez-Bisbal, M.C., Boscá, I. (2007). Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis. Neurology, **1**: 63–67. http://dx.doi.org/10.1212/01.wnl.0000265054.08610.12

[50] Pivneva, T. (2009). Mechanisms Underlying the Process of Demyelination in Multiple Sclerosis. Neurophysiology, **41(5)**, 429-437 http://dx.doi.org/10.1007/s11062-010-9114-z

[51] Polman, C.H. & Hartung H. (1995). The treatment of multiple sclerosis: current and future. Curr Opin Neurol, **8**, 200-209. http://dx.doi.org/10.1097/00019052-199506000-00008

[52] Poser, C.M. & Brinar, V.V. (2004). Diagnostic criteria for multiple sclerosis: an historical review. Clin Neurol Neurosurg, **106 (3)**, 147–58. http://dx.doi.org/10.1016/j.clineuro.2004.02.004

[53] Prat, A., Al-Asmi, A., Duquette, P., Antel, J.P. (1999). Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy. Ann Neurol, **46**:253-256. http://dx.doi.org/10.1002/1531-8249(199908)46:2<253::AID-ANA16>3.0.CO;2-C

[54] Romine, J.S., Sipe, J.C., Koziol, J.A., Zyroff, J. & Beutler, E. (1999). A double blind, placebo-controlled, randomised trial of cladribine in relapsing-remitting multiple sclerosis. Proc Assoc Am Phys 1999; 111:35-44. http://dx.doi.org/10.1046/j.1525-1381.1999.09115.x

[55] Rosati, G. (2001). The prevalence of multiple sclerosis in the world : an update. Neurol. Sci, **22(2)**, 117-39. http://dx.doi.org/10.1007/s100720170011

[56] Rovaris, M., Confavreux, C., Furlan, R., Kappos, L., Comi, G., Filippi, M. (2006). Secondary progressive multiple sclerosis: current knowledge and future challenges. Lancet Neurol, **5 (4)**, 343–354. http://dx.doi.org/10.1016/S1474-4422(06)70410-0

[57] Rudick, R.A., Lee, J.C., Simon, J., Ransohoff, R.M. & Fisher, E. (2004). Defining interferon b response status in multiple sclerosis patients. Ann Neurol, **56**, 548- 555. http://dx.doi.org/10.1002/ana.20224

[58] Schrijver, H.M., Crusius, J.B., Uitdehaag, B.M., Garcia Gonzalez, M.A., Kostense, P.J. & Polman, CH. (1999). Association of interleukin-1 beta and interleukin-1 receptor antagonist genes with disease severity in MS. Neurology, **52**, 595– 599. http://dx.doi.org/10.1212/WNL.52.3.595

[59] Smith, D.R., Weinstock-Guttman, B., Cohen. JA, et al. (2005). A randomized blinded trial of combination therapy with cyclophosphamide in patients with active multiple sclerosis on interferon beta. Mult Scler, **11**, 573-582. http://dx.doi.org/10.1191/1352458505ms1210oa

[60] Sotelo, J., Martínez-Palomo, A., Ordo-ez, G., Pineda, B. (2008). Varicella-zoster virus in cerebrospinal fluid at relapses of multiple sclerosis". Ann. Neurol, **63 (3)**, 303–311. http://dx.doi.org/10.1002/ana.21316

[61] Steultjens, E.M., Dekker, J., Bouter, L.M., Leemrijse, C.J., van, D. & Ende, C.H. (2005). Evidence of the efficacy of occupational therapy in different conditions: an overview of systematic reviews. Clinical rehabilitation, **19 (3)**: 247–54. http://dx.doi.org/10.1191/0269215505cr870oa

[62] Thompson, A.J. (2005). Neurorehabilitation in multilple sclerosis: foundations, facts and fiction. Current Opinion in Neurology, **18**: 267-271. http://dx.doi.org/10.1097/01.wco.0000169743.37159.a0

[63] Trapp, B.D., Wujek, J.R., Criste, G.A., et al. (2007). Evidence for synaptic stripping by cortical microglia. Glia, **55,** 360 –368. http://dx.doi.org/10.1002/glia.20462

[64] Tremlett, H.L, Luscombe, D.K. & Wiles, C.M. (1998). Use of corticosteroids in multiple sclerosis by consultant neurologists in the United Kingdom. J Neurol Neurosurg Psych, **65**: 362-5. http://dx.doi.org/10.1136/jnnp.65.3.362

[65] Tsang, B.K. & Macdonell, .R. (2011). Multiple sclerosis- diagnosis, management and prognosis. Australian family physician, **40 (12)**: 948–55.

[66] Tubridy, N., Behan, P.O., Capildeo, R., Chaudhuri, A., Forbes, R. & Hawkins, C.P. : The effect of anti-alpha 4 integrin antibody on brain lesion activity in MS. Neurology 1999; **53**:466-72. http://dx.doi.org/10.1212/WNL.53.3.466

[67] Weiner, H.L. (2004). Multiple sclerosis is an inflammatory T-cellmediated autoimmune disease. Arch Neurol, **61**, 1613–1615 http://dx.doi.org/10.1001/archneur.61.10.1613

[68] Weinshenker, B.H. (1998). The natural history of multiple sclerosis: up date. Semin Neurol, **18**, 301-307. http://dx.doi.org/10.1055/s-2008-1040881

[69] Weinshenker, B.G., Obrien, P.C, Petterson, T.M., Noseworthy, J.H., Lucchinetti, C.F. & Dodick, D.W. (1999). A randomised trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol, **46**:878-86. http://dx.doi.org/10.1002/1531-8249(199912)46:6<878::AID-ANA10>3.0.CO;2-Q

[70] Weinstock-Guttman, B., Ransohoff, R.M., Kinkel, R.P., Rudick, R.A. (1995). The interferons: biological effects, mechanisms of action, and use in multiple sclerosis. Ann Neurol, **37**, 7- 15. http://dx.doi.org/10.1002/ana.410370105

[71] WHO. (2006). Neurological disorders: public health challenges, 85-94.

[72] Yong, V.W., Chabot, S., Stuve, O. & Williams, G. (1998). Interferon beta in the treatment of multiple sclerosis-mechanisms of action. Neurology, **51**:682-689. http://dx.doi.org/10.1212/WNL.51.3.682

[73] Yudkin, P.L., Ellison, G.W., Ghezzi, A., Goodkin, D.E., Hughes, R.A. & Mc Pherson, K. (1991). Overview of azathioprine treatment in multiple sclerosis. Lancet, **338**:1051-55. http://dx.doi.org/10.1016/0140-6736(91)91909-E